Viking Therapeutics (NASDAQ:VKTX) Upgraded at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Viking Therapeutics (NASDAQ:VKTX - Free Report) to a strong-buy rating in a report published on Tuesday,Zacks.com reports. Cantor Fitzgerald also issued estimates for Viking Therapeutics' FY2025 earnings at ($2.57) EPS.

A number of other equities analysts have also commented on the stock. Maxim Group dropped their price target on shares of Viking Therapeutics from $120.00 to $70.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. HC Wainwright restated a "buy" rating and issued a $102.00 price objective on shares of Viking Therapeutics in a research note on Thursday, April 24th. Morgan Stanley dropped their target price on shares of Viking Therapeutics from $105.00 to $102.00 and set an "overweight" rating on the stock in a research report on Thursday, April 24th. Truist Financial restated a "buy" rating and set a $75.00 price objective (down previously from $95.00) on shares of Viking Therapeutics in a report on Monday, April 28th. Finally, Raymond James increased their target price on shares of Viking Therapeutics from $122.00 to $125.00 and gave the company a "strong-buy" rating in a research note on Thursday, February 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $87.15.

Viking Therapeutics Trading Down 1.0 %

VKTX stock traded down $0.29 during midday trading on Tuesday, reaching $29.08. The company had a trading volume of 1,349,658 shares, compared to its average volume of 4,094,355. The company has a 50 day moving average of $26.18 and a two-hundred day moving average of $39.03. Viking Therapeutics has a 1 year low of $18.92 and a 1 year high of $81.86. The company has a market capitalization of $3.27 billion, a P/E ratio of -29.08 and a beta of 0.75.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The biotechnology company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.10). The company's quarterly revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.26) earnings per share. On average, sell-side analysts anticipate that Viking Therapeutics will post -1.56 earnings per share for the current year.

Insider Buying and Selling at Viking Therapeutics

In other news, Director Sarah Kathryn Rouan acquired 1,240 shares of the business's stock in a transaction that occurred on Monday, March 31st. The shares were bought at an average price of $24.15 per share, with a total value of $29,946.00. Following the acquisition, the director now directly owns 1,240 shares in the company, valued at $29,946. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 4.10% of the company's stock.

Institutional Trading of Viking Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Formidable Asset Management LLC boosted its position in shares of Viking Therapeutics by 32.1% during the 1st quarter. Formidable Asset Management LLC now owns 40,768 shares of the biotechnology company's stock valued at $985,000 after purchasing an additional 9,896 shares in the last quarter. Kintayl Capital LP lifted its holdings in shares of Viking Therapeutics by 96.0% in the first quarter. Kintayl Capital LP now owns 99,973 shares of the biotechnology company's stock valued at $2,414,000 after purchasing an additional 48,979 shares in the last quarter. Wealthfront Advisers LLC lifted its stake in Viking Therapeutics by 76.1% during the 1st quarter. Wealthfront Advisers LLC now owns 8,759 shares of the biotechnology company's stock valued at $212,000 after acquiring an additional 3,786 shares in the last quarter. Signaturefd LLC grew its stake in shares of Viking Therapeutics by 126.8% in the 1st quarter. Signaturefd LLC now owns 2,830 shares of the biotechnology company's stock worth $68,000 after acquiring an additional 1,582 shares in the last quarter. Finally, CWM LLC grew its position in Viking Therapeutics by 36.1% in the 1st quarter. CWM LLC now owns 3,542 shares of the biotechnology company's stock worth $86,000 after purchasing an additional 939 shares in the last quarter. 76.03% of the stock is currently owned by institutional investors and hedge funds.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.